SCHEMBL5165563

SCHEMBL5165563

CC(C)(C)OC(=O)CNCCC1CCC(CC(=O)O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
KMT2A Q03164 2/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ANPEP P15144 1/20 0.33
ENPEP Q07075 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
EPHX1 P07099 1/20 0.32
S1PR1 P21453 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
NR1H2 P55055 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
SLC6A1 P30531 2/20 0.31
GABRA5 P31644 2/20 0.31
GABRB2 P47870 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5164415 1.00 CTSS (0.34) CTSSCTSKKMT2AMAOAMAOB
SCHEMBL5025642 0.87 KMT2A (0.46) CTSSCTSKKMT2AMAOAMAOB
SCHEMBL6018875 0.81 ALDH1A1 (0.39) CTSKKMT2AALDH1A1L3MBTL1MAPT
SCHEMBL6018870 0.81 ALDH1A1 (0.39) CTSKKMT2AALDH1A1L3MBTL1MAPT
SCHEMBL6018740 0.79 CA12 (0.31) KMT2AMAOAMAOBALDH1A1L3MBTL1
SCHEMBL6018422 0.79 GPR119 (0.33) KMT2AALDH1A1L3MBTL1
SCHEMBL6019038 0.79 KMT2A (0.39) CTSSCTSKKMT2AALDH1A1S1PR1
SCHEMBL30028645 0.79 KMT2A (0.41) CTSSCTSKKMT2AALDH1A1EPHX1
SCHEMBL9563635 0.78 SLC6A1 (0.41) KMT2AMAOAMAOBALDH1A1L3MBTL1
SCHEMBL9089608 0.78 SLC6A1 (0.41) KMT2AMAOAMAOBALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1768658-A1 HYDROXYALKYLAMIDES F.HOFFMANN-LA ROCHE AG (CH) 2007-04-04 EP disclosed
WO-2006125451-A1 HYDROXYALKYLAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2006-11-30 WO disclosed
US-6965048-B2 Hydroxyalkylamide derivatives HOFFMANN-LA ROCHE INC. (US) 2005-11-15 US disclosed
US-20050009906-A1 e.g., N-{4-[3-(4-Hydroxy-piperidin-1-yl)-3-oxo-propoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide and p-chlorophenyl methyl-(2-{4-[methyl-(2-methylcarbamoyl-ethyl)-carbamoyl]-cyclohexyl}-ethyl)-carbamate F. HOFFMAN-LA ROCHE AG (CH) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009906-A1 e.g., N-{4-[3-(4-Hydroxy-piperidin-1-yl)-3-oxo-propoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide and p-chlorophenyl methyl-(2-{4-[methyl-(2-methylcarbamoyl-ethyl)-carbamoyl]-cyclohexyl}-ethyl)-carbamate CYP51A1, CYP46A1, LSS CTSS 235/4885CTSK 641/4885KMT2A 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.